-
About three million U.S. women experience heavy menstrual bleeding each year.1 With the recent Food and Drug Administration (FDA) approval of Natazia (Bayer HealthCare Pharmaceuticals, Wayne, NJ) for treatment in women who choose an oral contraceptive (OC), clinicians now have another therapeutic option.
-
Ulipristal acetate, the drug recently approved as an emergency contraceptive in the United States (Ella, Watson Pharmaceuticals, Morristown, NJ), is being eyed for other gynecologic uses. In research looking at women with symptomatic fibroids who were planning to undergo surgery, treatment with the selective progesterone-receptor modulator was effective in controlling excessive bleeding and reducing fibroid size at 13 weeks.
-
Results from a large, long-running Scandinavian study provides convincing evidence that combined oral contraceptives (OCs) alleviate the symptoms of dysmenorrhea, painful menstrual periods.
-
New research indicates that the human papillomavirus vaccine (HPV) Gardasil (Merck & Co.) does not trigger autoimmune conditions such as lupus, rheumatoid arthritis, type 1 diabetes, or multiple sclerosis after vaccination in young women.
-
Has your clinic telephone been ringing recently with calls from women who have heard about a birth control pill recall? Chances are, few, if any, of your patients were using the affected oral contraceptives (OCs).
-
Where do long-acting reversible contraceptives (LARC) fit in at your facility? How are you encouraging women to use the "Get It and Forget It" methods? If you are seeing low numbers of women choosing intrauterine devices (IUDs) or the contraceptive implant, you might want to change your counseling strategy.
-
Now that male circumcision has been associated with a lower risk for HIV infection in international observational studies and in three randomized controlled clinical trials, international health officials are looking at options in making it more available to men at risk.
-
The results of the PEARL I and PEARL II studies were published recently in the same issue of the New England Journal of Medicine. Both were well-designed, randomized, controlled, double-blinded studies that assessed the safety and efficacy of ulipristal acetate (UPA) for the treatment of symptomatic uterine fibroids.
-
In this issue: Statins and diabetes risk; new treatment guideline for diabetes; new pertussis vaccine recommendation; antibiotics and rhinosinusitis; fluoroquinolones and cystitis; and FDA actions.
-
It has been long recognized that thrombocytosis (defined as a platelet count > 450,000/mm3) frequently accompanies the diagnosis of advanced cancer and has been associated with poor outcomes.
